Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Oral Mucositis - Overview

Oral Mucositis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oral Mucositis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oral Mucositis - Companies Involved in Therapeutics Development

Alivio Therapeutics Inc

Allander Biotechnologies LLC

BIOCND Inc

Clevexel Pharma SAS

Enzychem Lifesciences Corp

Galera Therapeutics Inc

Genekey Biotech Chengdu Co Ltd

GlycoMira Therapeutics Inc

Humanetics Corp

Innovation Pharmaceuticals Inc

Lakewood-Amedex Inc

Matrix Biomed Inc

Monopar Therapeutics Inc

Oragenics Inc

Soligenix Inc

Spectrum Pharmaceuticals Inc

Spherium Biomed SL

Sunny Pharmtech Inc

Oral Mucositis - Drug Profiles

AG-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avasopasem manganese - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clonidine ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0095 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dusquetide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

genistein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoleucovorin calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mosedipimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nu-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pralatrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize KGFR for Chemotherapy Induced Gastrointestinal Mucositis and Oral Mucositis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tempol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oral Mucositis - Dormant Projects

Oral Mucositis - Discontinued Products

Oral Mucositis - Product Development Milestones

Featured News & Press Releases

Nov 25, 2019: Innovation Pharmaceuticals and FDA agree to waive initial pediatric study plan requirement regarding brilacidin for the prevention of oral mucositis

Nov 13, 2019: Innovation Pharmaceuticals: Oral Cancer on the Rise; company offers perspectives on opportunity of Brilacidin for the prevention of Oral Mucositis

Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases

Oct 08, 2019: Galera Therapeutics announces two-year tumor outcomes data for GC4419

Oct 03, 2019: Soligenixs SGX942 on track to fill unmet medical need; targeting oral mucositis in patients with head and neck cancer

Sep 30, 2019: Oragenics presents interim data on the AG013 phase 2 clinical trial at the European Society for Medical Oncology Congress 2019

Sep 25, 2019: Oragenics announces phase 2 clinical trial of AG013 reaches enrollment of 158 patients

Sep 23, 2019: Oragenics to present interim data on AG013 at the European Society of Medical Oncology Congress

Aug 28, 2019: Soligenix announces positive recommendation by Independent Data Monitoring Committee on its phase 3 clinical trial of SGX942 for the treatment of oral mucositis in Head and Neck Cancer

Aug 15, 2019: Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

May 29, 2019: Innovation Pharmaceuticals provides update on brilacidin at 2019 BIO International Convention

May 20, 2019: Oragenics provides development update of AG013 for oral mucositis

May 01, 2019: Innovation Pharmaceuticals receives FDA End-of-Phase 2 meeting minutes

Apr 23, 2019: Innovation Pharmaceuticals - JAMA Article reinforces need for novel oral mucositis treatments in supportive cancer care

Apr 09, 2019: Innovation Pharmaceuticals reports enhancements in manufacture of Brilacidin phase 3 drug supply

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Oral Mucositis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape.

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Oral Mucositis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oral Mucositis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 1 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oral Mucositis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oral Mucositis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oral Mucositis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.